XML 22 R8.htm IDEA: XBRL DOCUMENT
v3.4.0.3

Condensed Consolidated Financial Statements Detail | 3 Months Ended
--- | ---
Mar. 31, 2016
Condensed Consolidated Financial Statements Detail [Abstract] |
Condensed Consolidated Financial Statements Detail | 3. Condensed Consolidated Financial Statements Detail Cash and Cash Equivalents As of March 31, 2016, cash and cash equivalents consisted of demand deposits of $3.0 million and money market funds of $43.1 million with maturities of less than 90 days at the date of purchase. As of December 31, 2015, cash and cash equivalents consisted of demand deposits of $23.2 million and money market funds of $42.6 million with maturities of less than 90 days at the date of purchase. Marketable Securities At March 31, 2016 and December 31, 2015, marketable securities consisted of an investment in the common stock of a public entity of $0.5 million. The Company had an unrealized loss of $42,000 associated with its marketable securities as of March 31, 2016. At each reporting date, the Company performs an evaluation of its equity securities to determine if unrealized losses are other-than-temporary. In performing this assessment, the Company determines whether it expects the security to recover in the near term and considers its ability and intent to hold the security until anticipated recovery. This determination considers the duration and severity of the impairment and the financial condition of the investment as well as the Company’s ability to hold the investment until a recovery of fair value. As of March 31, 2016, the Company determined that the unrealized loss for its marketable securities is not an other-than-temporary impairment. Accrued and Other Liabilities Accrued and other liabilities consisted of the following (in thousands):
|  | March 31, 2016 |  |  | December 31, 2015 |
Accrued payroll and other benefits |  | $ | 1,573 |  |  | $ | 2,156 |
Deferred rent |  |  | 724 |  |  |  | 608 |
Accrued clinical trial costs |  |  | 517 |  |  |  | 406 |
Accrued legal and accounting fees |  |  | 511 |  |  |  | 517 |
Accrued incentive compensation |  |  | 243 |  |  |  | 2,609 |
Accrued restructuring costs |  |  | 138 |  |  |  | 459 |
Other |  |  | 681 |  |  |  | 270 |
Total |  | $ | 4,387 |  |  | $ | 7,025 |
Net Loss Per Share of Common Stock Potentially dilutive securities are excluded from the calculation of diluted net loss per share of common stock if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):
|  | Three Months Ended March 31, |
|  | 2016 |  |  | 2015 |
Common stock options and RSUs |  |  | 10,704 |  |  |  | 8,756 |
Warrants for common stock |  |  | 18,230 |  |  |  | 20,690 |
Total |  |  | 28,934 |  |  |  | 29,446 |

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Condensed Consolidated Financial Statements Detail [Abstract] + References No definition available. + Details
Name: | xoma_CondensedConsolidatedFinancialStatementsDetailAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration